The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula
Double-blind Randomized Parallel Contrast Clinical Study of Yiqilishui Formula on Sepsis Induced Myocardial Dysfunction
Dongzhimen Hospital, Beijing
80 participants
Nov 20, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if Chinese medicine - Yiqilishui formula works to treat sepsis-induced myocardial dysfunction (SIMD). It will also learn about the safety of Yiqilishui formula. The main questions it aims to answer are: * Compared with conventional western traetment alone, can supplementing conventional Western treatment with Yiqilishui formula better improve the heart function and reduce mortality of participants with SIMD? * What medical problems do participants have when taking Yiqilishui formula? Researchers will compare Yiqilishui formula to a placebo (a look-alike substance that contains no drug) to see if Yiqilishui formula works to treat SIMD. Participants will: * Take Yiqilishui formula granules or placebo twice daily for 7 days, while receiving standard conventional Western treatment. * Undergo blood drawing, electrocardiogram and transthoracic echocardiography at enrollment, on the 3rd day, the 7th day, and the 14th day after enrollment.
Eligibility
Inclusion Criteria6
- Patients hospitalized in the ICU of Tongzhou Traditional Chinese Medicine Hospital and Dongzhimen Hospital of Beijing University of Chinese Medicine between January 2024 and December 2026.
- Patients diagnosed with SIMD and qi deficiency and water flooding syndrome.
- Aged 50 to 85 years.
- SOFA score: 2 to 12 points.
- Diagnosis of SIMD within 24 hours.
- Signed informed consent by the patient or their family.
Exclusion Criteria12
- Subjects diagnosed with acute coronary syndrome.
- Subjects with heart failure caused by cardiomyopathies such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, or hypothyroid cardiomyopathy.
- Subjects with heart failure caused by structural heart abnormalities, arrhythmias, pulmonary heart disease, or cardiorenal syndrome.
- Subjects with severe primary diseases affecting survival, including uncontrolled, unresectable metastatic malignant tumors, hematologic diseases, and HIV.
- Subjects with liver or kidney dysfunction, with an individual SOFA score of ≥3 for liver or kidney function.
- Subjects who have used immunosuppressants continuously in the last 6 months or have undergone organ transplantation.
- Subjects who have used corticosteroids (equivalent to methylprednisolone ≥20mg/day) continuously within 7 days prior to enrollment.
- Subjects who have used Chinese herbal medicines or Chinese patent medicine replenishing qi, activating blood circulation and facilitating diuresis within 14 days prior to enrollment.
- Subjects deemed unable to take decoctions by clinicians.
- Pregnant or breastfeeding women.
- Subjects who have participated in other clinical trials within the last 30 days.
- Subjects deemed unable to complete or unsuitable for this study by the researchers (e.g., expected death within 48 hours or refusal of active treatment).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
5% Yiqilishui Granules + 95% Dextrin;
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06686355